title: Irinotecan-induced dysarthria.
abstract: Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second-line therapy with irinotecan and developed isolated transient dysarthria (with normal MR imaging of the brain) following each administration of irinotecan. Neurological and logopedical evaluation revealed that the dysarthria predominantly resulted from a reduced capacity in fine-tuning of motor functions of the tip of the tongue and a minimal reduction in the power of speech at labiodental contact. As hypoglossal nerve activity has been reported to be especially susceptible to cholinergic stimulation and irinotecan can cause cholinergic side effects by binding to and inactivating acetylcholinesterase, we suspect this mechanism to be responsible for irinotecan-induced dysarthria.
authors.affiliation: Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: Albertine J
authors.initials: AJ
authors.lastname: Dressel
authors.forename: Johannes C
authors.initials: JC
authors.lastname: van der Mijn
authors.forename: Ijke J
authors.initials: IJ
authors.lastname: Aalders
authors.forename: Rico N P M
authors.initials: RN
authors.lastname: Rinkel
authors.forename: Hans J
authors.initials: HJ
authors.lastname: van der Vliet